LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers

2005 ◽  
Vol 28 (4) ◽  
pp. 463-468 ◽  
Author(s):  
Ji Hye Yun ◽  
Ja Hye Myung ◽  
Hye Jin Kim ◽  
Sibeum Lee ◽  
Jong-Sei Park ◽  
...  
Keyword(s):  
Oral Administration ◽  
Human Volunteers ◽  
Bioavailability Study ◽  
Imidapril Hydrochloride

Plasma pyroglutamic acid levels after oral administration of monosodium glutamate to human volunteers

1983 ◽  
Vol 15 (2-3) ◽  
pp. 123-129 ◽  
Author(s):  
Pietro Ghezzi ◽  
Silvio Garattini ◽  
Silvio Caccia ◽  
Mario Salmona ◽  
Maria Grazia Zanini
Keyword(s):  
Oral Administration ◽  
Monosodium Glutamate ◽  
Pyroglutamic Acid ◽  
Human Volunteers

Bioavailability Study of Glycyrrhetic Acid after Oral Administration of Glycyrrhizin in Rats; Relevance to the Intestinal Bacterial Hydrolysis

1996 ◽  
Vol 48 (9) ◽  
pp. 902-905 ◽  
Author(s):  
Shuichi Takeda ◽  
Kazuhisa Ishihara ◽  
Yoko Wakui ◽  
Sakae Amagaya ◽  
Masao Maruno ◽  
...  
Keyword(s):  
Oral Administration ◽  
Glycyrrhetic Acid ◽  
Bioavailability Study

scholarly journals Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Giovanna Petrangolini ◽  
Fabrizio Corti ◽  
Massimo Ronchi ◽  
Lolita Arnoldi ◽  
Pietro Allegrini ◽  
...  
Keyword(s):  
Oral Administration ◽  
Healthy Volunteers ◽  
Plasma Concentrations ◽  
Pharmacokinetic Profile ◽  
Healthy Human ◽  
Food Grade ◽  
Dose Linearity ◽  
Human Volunteers ◽  
Intestinal Fluids

Objective. To evaluate in vitro solubility, bioaccessibility, and cytotoxic profile, together with a pharmacokinetic profile by oral administration to healthy volunteers of a novel food-grade berberine formulation (BBR-PP, i.e., berberine Phytosome®). Results. An in vitro increase of solubility in simulated gastric and intestinal fluids and an improved bioaccessibility at intestinal level along with a lower cytotoxicity with respect to berberine were observed with BBR-PP. The pharmacokinetic profile of the oral administration to healthy volunteers confirmed that berberine Phytosome® significantly ameliorated berberine absorption, in comparison to unformulated berberine, without any observed side effects. The berberine plasma concentrations observed with both doses of BBR-PP were significantly higher than those seen after unformulated berberine administration, starting from 45 min (free berberine) and 30 min (total berberine). Furthermore, BBR-PP improved berberine bioavailability (AUC) was significantly higher, around 10 times on molar basis and with observed dose linearity, compared to the unformulated berberine. Conclusion. These findings open new perspectives on the use of this healthy berberine formulation in metabolic discomforts.

Serum Quinidine Determination: Comparison of Mass-Spectrometric and Extraction-Fluorescence Methods

1982 ◽  
Vol 16 (9) ◽  
pp. 693-695 ◽  
Author(s):  
Gary H. Smith ◽  
René H. Levy
Keyword(s):  
Care Setting ◽  
Plasma Concentrations ◽  
Mass Spectrometric ◽  
Spectrometric Method ◽  
Mass Spectrometric Method ◽  
Fluorometric Method ◽  
Human Volunteers ◽  
Bioavailability Study ◽  
Normal Human ◽  
Serum Quinidine

A comparison of two analytical methods of quinidine plasma determination—the modified extraction fluorometric method and the mass spectrometric method—was made. Plasma supplies collected at steady state from normal human volunteers participating in a bioavailability study were analyzed, using both methods. A total of 359 samples were analyzed. Comparison of both sets of values, by linear regression, yielded an r2 value of 0.84. The results of this comparison were consistent with the results reported by others, confirming that the commonly used extraction fluorometric method of quinidine determination is sufficiently accurate for monitoring quinidine plasma concentrations in the patient care setting, as well as for bioavailability comparisons between products.

S4-04-01: CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609

2012 ◽  
Vol 8 (4S_Part_20) ◽  
pp. S743-S743 ◽  
Author(s):  
Bruce Albala ◽  
June M. Kaplow ◽  
Robert Lai ◽  
Mark Matijevic ◽  
Jagadeesh Aluri ◽  
...  
Keyword(s):  
Oral Administration ◽  
The Novel ◽  
Bace1 Inhibitor ◽  
Human Volunteers
Sign in / Sign up

Export Citation Format

Share Document